Payment overview · 2025
General Payments
$887.23
51 reported records · 20 companies
Healthcare provider profile · identity verified
Charles K Phillips, MD
Allopathic & Osteopathic Physicians|Family Medicine · NEWPORT NEWS, VA · NPI 1821089905
Verified facts
What the public records show
CMS Open Payments records show Charles K Phillips, MD received $887.23 in general payments during 2025 across 51 reported records.
ABBVIE INC. accounted for 16.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $145.39 | 16.4% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $89.33 | 10.1% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $78.70 | 8.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $78.53 | 8.8% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $66.73 | 7.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $61.34 | 6.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $45.60 | 5.1% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $44.06 | 5.0% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $40.57 | 4.6% | 2 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $39.71 | 4.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.71 | 3.7% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $21.82 | 2.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.48 | 2.3% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.44 | 2.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.76 | 2.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.68 | 2.1% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $17.80 | 2.0% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $16.29 | 1.8% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.17 | 1.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.12 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $887.23 | 51 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $89.33 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $89.33 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $75.48 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $73.51 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $66.73 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $60.54 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $56.72 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $45.48 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $45.48 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $41.32 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $41.32 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $40.57 | 2 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $39.71 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $31.92 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $25.56 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.48 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.48 | 1 | 2025 |
Source payment records
|
|||||
| AZMIRO Normalized: azmiro |
Drug | Azurity Pharmaceuticals, Inc. | $20.44 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.05 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.12 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.68 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.66 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 53 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 110 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
105 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
110 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 438 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 416 | 96 |
| Atorvastatin Calcium | Atorvastatin Calcium | 414 | 113 |
| Amlodipine Besylate | Amlodipine Besylate | 410 | 122 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 307 | 98 |
| Simvastatin | Simvastatin | 307 | 86 |
| Omeprazole | Omeprazole | 291 | 85 |
| Metformin Hcl | Metformin Hcl | 249 | 78 |
| Lisinopril | Lisinopril | 247 | 65 |
| Alprazolam | Alprazolam | 232 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 213 | 55 |
| Gabapentin | Gabapentin | 209 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 200 | 63 |
| Sertraline Hcl | Sertraline Hcl | 186 | 51 |
| Lorazepam | Lorazepam | 181 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 175 | 54 |
| Montelukast Sodium | Montelukast Sodium | 154 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 151 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 145 | 44 |
| Prednisone | Prednisone | 143 | 103 |
| Furosemide | Furosemide | 137 | 50 |
| Famotidine | Famotidine | 134 | 38 |
| Cephalexin | Cephalexin | 129 | 103 |
| Escitalopram Oxalate | Escitalopram Oxalate | 126 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 113 | 27 |
| Ozempic | Semaglutide | 110 | 24 |
| Synthroid | Levothyroxine Sodium | 105 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 104 | 14 |
| Allopurinol | Allopurinol | 92 | 27 |
| Clonidine Hcl | Clonidine Hcl | 90 | 25 |
| Oxybutynin Chloride | Oxybutynin Chloride | 90 | 25 |
| Trazodone Hcl | Trazodone Hcl | 90 | 22 |
| Meloxicam | Meloxicam | 89 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 89 | 27 |
| Glipizide | Glipizide | 88 | 22 |
| Carvedilol | Carvedilol | 87 | 28 |
| Telmisartan | Telmisartan | 87 | 28 |
| Ezetimibe | Ezetimibe | 86 | 24 |
| Repaglinide | Repaglinide | 81 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 76 | 19 |
| Amoxicillin | Amoxicillin | 74 | 57 |
| Donepezil Hcl | Donepezil Hcl | 71 | 16 |
| Spironolactone | Spironolactone | 70 | 23 |
| Baclofen | Baclofen | 69 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 69 | 23 |
| Bupropion Xl | Bupropion Hcl | 67 | 18 |
| Tramadol Hcl | Tramadol Hcl | 67 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 21 |
| Atenolol | Atenolol | 65 | 18 |
| Potassium Chloride | Potassium Chloride | 65 | 23 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 62 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 18 |
| Valacyclovir | Valacyclovir Hcl | 62 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 20 |
| Valsartan | Valsartan | 59 | 16 |
| Eliquis | Apixaban | 53 | 13 |
| Celecoxib | Celecoxib | 51 | suppressed |
| Clonazepam | Clonazepam | 48 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 15 |
| Memantine Hcl | Memantine Hcl | 47 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 44 | suppressed |
| Temazepam | Temazepam | 44 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 43 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | suppressed |
| Lovastatin | Lovastatin | 43 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 43 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 41 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | 12 |
| Propranolol Hcl | Propranolol Hcl | 40 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Fluconazole | Fluconazole | 33 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Azithromycin | Azithromycin | 32 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 32 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | 17 |
| Estradiol | Estradiol | 30 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 30 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | 23 |
| Azelastine Hcl | Azelastine Hcl | 29 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Eszopiclone | Eszopiclone | 29 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 29 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 28 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | 11 |
| Methocarbamol | Methocarbamol | 27 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 26 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Nystatin | Nystatin | 26 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 26 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 20 |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | 14 |
| Glimepiride | Glimepiride | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Metronidazole | Metronidazole | 16 | 11 |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $887.23 · 51 records | ABBVIE INC. | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, AZMIRO, Auvelity, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, GARDASIL 9, ImmunoCAP, JATENZO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, Sunosi, TRELEGY ELLIPTA, UBRELVY, UNITHROID, VRAYLAR, Wegovy, XIFAXAN, XYOSTED, ZAVZPRET, ZEPBOUND, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error